Artificial Intelligence Expands the Destiny of DNA Analysis

International Biopharmaceutical Industry

DNA is the code that has defined humanity for millennia. Until more recently, DNA has determined destiny. There was no escaping its design and code for individuals. It was the code that says how long people will live and what they will likely die from, at least in terms of propensity and predisposition towards certain conditions, from heart disease to diabetes to  colon cancer. Ian Jenkins at Frelii discusses the true epigenetic correlations that impact the destiny of DNA and how it relates to individual health and wellbeing to emerge in ways never before imagined. Keep Reading

Frélii: Transforming Healthcare with AI and DNA Data Mining


Artificial intelligence (AI) and whole genome analysis are poised to turn the world of healthcare on its head. Advances in recent years have taken the cutting-edge technologies from science to reality, and one company is now using them to dramatically improve patient outcomes and make personalized medicine the norm. Already working with doctors and hospitals to mine DNA and use AI to provide better treatments much faster, Frélii, is working on its next goal: building an integration tool for medical devices so that the information generated from a device can be analyzed and delivered to the doctor in a more streamlined fashion.  Keep Reading

What Experts Have to Say About the Endocannabinoid System


Ian Jenkins, CEO of Frelii, a provider of DNA sequencing and genome analysis, wrote how nourishing the ECS can extend well past the two most popular cannabinoids. “Although most of the research is around THC and CBD, just about every cannabinoid can be thought of as nourishing.” Keep Reading